公开(公告)号：US11324693B2

公开(公告)日：2022-05-10

申请号：US16833883

申请日：2020-03-30

Applicant: MATI THERAPEUTICS INC.

Inventor： Deepank Utkhede ,  Catherine Jones ,  David Wiseman

IPC: A61F9/00 ,  A61F9/007 ,  A61K31/165 ,  A61K31/569 ,  A61K31/573 ,  A61K9/00 ,  A61K47/34 ,  A61K38/13 ,  A61K47/10 ,  A61K9/14

Abstract: A solid matrix sustained release ophthalmic formulation for topical delivery of a solid ophthalmic drug to the eye, medical devices, drug cores, drug inserts and drug delivery systems comprising the formulation, methods of manufacturing the formulation, medical devices and their methods thereof for delivering the ophthalmic drug for a treatment period provided herein. The formulation disclosed herein is an admixture of an ophthalmic drug, and a combination of a hydrophobic polymer, a hydrophilic polymer and a surfactant, wherein the drug is eluted daily over an extended period of time at therapeutic dose of drug.

公开(公告)号：US10603274B2

公开(公告)日：2020-03-31

申请号：US15722227

申请日：2017-10-02

Applicant: MATI THERAPEUTICS INC.

Inventor： Deepank Utkhede ,  Catherine Jones ,  David Wiseman

IPC: A61F9/00 ,  A61K31/165 ,  A61K31/569 ,  A61K38/13 ,  A61K47/10 ,  A61K9/00 ,  A61K47/34 ,  A61K9/14 ,  A61F9/007 ,  A61K31/573

Abstract: A solid matrix sustained release ophthalmic formulation for topical delivery of a solid ophthalmic drug to the eye, medical devices, drug cores, drug inserts and drug delivery systems comprising the formulation, methods of manufacturing the formulation, medical devices and their methods thereof for delivering the ophthalmic drug for a treatment period provided herein. The formulation disclosed herein is an admixture of an ophthalmic drug, and a combination of a hydrophobic polymer, a hydrophilic polymer and a surfactant, wherein the drug is eluted daily over an extended period of time at therapeutic dose of drug.